SAB Biotherapeutics, Inc. (SABS)
SABS Stock Price Chart
Explore SAB Biotherapeutics, Inc. interactive price chart. Choose custom timeframes to analyze SABS price movements and trends.
SABS Company Profile
Discover essential business fundamentals and corporate details for SAB Biotherapeutics, Inc. (SABS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
9 Feb 2021
Employees
63.00
CEO
Samuel J. Reich
Description
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.
SABS Financial Timeline
Browse a chronological timeline of SAB Biotherapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 7 May 2026
Upcoming earnings on 5 Nov 2025
EPS estimate is -$0.72.
Earnings released on 7 Aug 2025
EPS came in at -$1.09 falling short of the estimated -$0.82 by -32.93%.
Earnings released on 9 May 2025
EPS came in at -$0.56 surpassing the estimated -$1.00 by +44.00%.
Earnings released on 28 Mar 2025
EPS came in at -$1.23 falling short of the estimated -$1.16 by -6.03%, while revenue for the quarter reached $100.00K , missing expectations by -16.67%.
Earnings released on 6 Nov 2024
EPS came in at -$1.12 falling short of the estimated -$1.07 by -4.67%, while revenue for the quarter reached -$410.00 , missing expectations by -100.27%.
Earnings released on 8 Aug 2024
EPS came in at -$0.79 surpassing the estimated -$1.13 by +30.09%, while revenue for the quarter reached $263.14K .
Earnings released on 20 May 2024
EPS came in at -$0.54 surpassing the estimated -$0.98 by +44.90%, while revenue for the quarter reached $944.58K .
Earnings released on 1 Apr 2024
EPS came in at -$3.38 falling short of the estimated -$0.62 by -445.16%, while revenue for the quarter reached $305.01K .
Stock split effective on 5 Jan 2024
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 13 Nov 2023
EPS came in at -$1.00 matching the estimated -$1.00, while revenue for the quarter reached $1.27M , beating expectations by +10.49K%.
Earnings released on 21 Aug 2023
EPS came in at -$1.40 surpassing the estimated -$1.60 by +12.50%, while revenue for the quarter reached $85.52K , missing expectations by -79.14%.
Earnings released on 16 May 2023
EPS came in at -$1.50 falling short of the estimated -$0.80 by -87.50%, while revenue for the quarter reached $600.00K , missing expectations by -76.38%.
Earnings released on 14 Apr 2023
EPS came in at -$1.56 falling short of the estimated -$0.04 by -3.81K%, while revenue for the quarter reached $2.16M , missing expectations by -66.75%.
Earnings released on 15 Nov 2022
EPS came in at -$1.60 falling short of the estimated -$1.40 by -14.29%, while revenue for the quarter reached $3.59M , missing expectations by -39.18%.
Earnings released on 10 Aug 2022
EPS came in at -$1.10 surpassing the estimated -$1.30 by +15.38%, while revenue for the quarter reached $6.35M , missing expectations by -41.19%.
Earnings released on 12 May 2022
EPS came in at -$1.50 falling short of the estimated -$1.20 by -25.00%, while revenue for the quarter reached $11.80M , beating expectations by +2.93%.
Earnings released on 29 Mar 2022
EPS came in at -$0.66 falling short of the estimated -$0.11 by -500.00%, while revenue for the quarter reached $60.88M , meeting expectations.
Earnings released on 22 Nov 2021
EPS came in at -$0.02 surpassing the estimated -$0.09 by +77.78%, while revenue for the quarter reached $14.70M , missing expectations by -13.00%.
Earnings released on 9 Aug 2021
EPS came in at -$0.68 .
Earnings released on 21 May 2021
EPS came in at $0.32 .
Earnings released on 2 Apr 2021
EPS came in at -$0.01 .
SABS Stock Performance
Access detailed SABS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.